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In this paper we develop a novel valuation model and methodology to value a pharmaceutical
R&D project based on real options approach. The real options approach enables the possibility
of optimally abandon the project before completion whenever the investment cost turns out to be
larger than the expected net cash flow stream. On the other hand, the proposed model accounts
for two different sources of uncertainty, those are technical and economic risk. This model incor-
porates a novel economic state vector where each economic state captures the interaction among
different market and economic forces using Fourier series as the particular basis for the economic
function space. In this sense, Fourier series are considered as an aggregate of forces playing a
relevant role in the process evolution determining the cash flow structure and also allowing us to
properly define an economic scenario where the project will be developed.
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1 Introduction
The pharmaceutical industry is one of the most dynamic and research-intensive industries in the
world. One distinctive characteristic of this sector is the high level of investment in research and
development, in fact the pharmaceutical industry has one of the highest R&D budget to sales revenue
ratio across industries. The aim of this paper is to provide a comprehensive tool and methodology to
value an R&D project considering that it is subjected to technical and economic uncertainty. Here
we focus the attention on pharmaceutical R&D projects, however the model and methodology used
can be easily extrapolated to any industry, say for instance mining projects.
Developing a new medicine is a challenging endeavour and the chances of success are extremely
low, there are several complex forces, both economic and technical, governing the drug development
process that are not entirely understood. The first obstacle arises during the early discovery stage
when the company has to wisely assign the appropriate amount of both financial and scientific
resources. Although the total cost to develop a new medicine varies from one to another it heavily
depends on the kind of compound used, the drug under development, and the likelihood of failure. In
terms of time to completion, a pharmaceutical R&D process can take, roughly speaking, between ten
to fifteen years since the early-stage discovery of a new compound up to the marketing approval and
market launch of the product, again it heavily depends on the drug or treatment. For some innovative
drugs or treatments both cost and time to completion are a significant source of uncertainty and
constitute the cost of innovation. On the other hand, many “new” medicines or treatments are just
improvements on existing drugs, in this case the cost and time to completion are quite standardized
and, although there is some uncertainty, the R&D financial and technological cost is considerable
lower.
The pharmaceutical market is extremely complex and has divided the public opinion in several
controversial topics such as animal testing, drug prices, lack of research interest for certain diseases,
public funding, and so on. As any other private company, pharmaceutical companies are ultimately
focused on increasing shareholder value. The public perception that privately research funding
is solely motivated by profit has increased the friction between shareholders’ return expectations
and the public notion of fairness. On this regard, it is important to point out that no matter
how big a pharmaceutical company is, it can only cover a small portion of breakthrough R&D
projects. Therefore, most pharmaceutical companies have to choose with financial wisdom each
project because simply they cannot afford to invest when the affected population is too poor to buy
the drug or the market niche is just too small to achieve a reasonable return on the investment.
Recently, the 2014 Ebola outbreak has revealed the lack of resources and effort assigned to fight
this virus while it was limited or contained within the African border, and the increased interest
when the virus crossed the European and American border and “opened a new market”. In this
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paper we are not going to discuss such controversial ethical issues, however our proposed model
incorporates a novel economic state vector where each economic state captures the interaction among
different market and economic forces using Fourier series as the particular basis for the economic
function space. Hence, our model can be used to depict any extreme economic situation and properly
value an R&D project targeting such market. Furthermore, since most drugs introduced by the
pharmaceutical industry are developed with some contribution from the public sector, see for instance
Cockburn and Henderson (2000), our model can be used to determine the appropriate amount of
taxpayer’s money to allocate in a specific project. On this regard, it is worth to mention that public
opinion is a strong force which can heavily affect the project value, its effects can also be modelled
with the appropriate terms in the Fourier expansion.
The objective of this paper is to provide a powerful and flexible valuation model and technol-
ogy accounting for technical and economic risk and considering all those relevant forces playing a
significant role in the project valuation and decision making process. The remainder of this paper
is structured as follows: Section 2 is devoted to literature review. In Section 3 we identify those
economic risk factors affecting the Pharmaceutical return process, and we also disentangle the in-
teraction across factors via spectral analysis. Section 4 presents the valuation model, technicalities,
and implications. In Section 5 we illustrate the numerical implementation of the posited model
and methodology, we perform a sensitivity and stress test analysis to determine the response of the
model to different scenarios. Finally, in Section 6 we make some concluding comments.
2 Literature review
There is a vast amount of literature based on real options and its application to R&D. Most of
the academic literature based on real option valuation consider as exogenous variable the value of
the project conditional to the successful completion of the research and development phase. For
instance, Madj and Pinduck (1987) use a Geometric Brownian motion process to model the time
evolution of the project’s market value. The authors show that the arrival of new information might
lead the firm to depart from the spending scenario originally planned, and conclude that traditional
discounted cash flow criteria do not capture the managerial decision flexibility and for that reason
are inadequate to properly value projects where the spending decisions and cash outlays occur
sequentially over time, there is a maximum rate at which outlays and construction can proceed, and
the project yields no cash return until it is actually completed. Furthermore, assuming that the
gross project value follows a Geometric Brownian motion, Trigeorgis (1993) analyses the valuation
of flexible capital budgeting projects with a collections of real options and examines the interactions
among these options identifying situations where option interactions can be small or large, negative
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or positive. Pennings and Sereno (2011) value a compound R&D option assuming a geometric
Brownian motion process for the underlying value of the project and considering a Poisson random
variable to depict the technical failure probability.
On this regard, our approach is closer to the work of Berk et al. (2003) and Schwartz (2004)
where the cash flows from the R&D project are modelled. In more detail, Berk et al. (2003)
develops and analyses a single R&D investment project modelling the cash flows from the project
with two stochastic processes, one of them tracking any possible catastrophic event and the other
process modelling the conditional cash flows the project would have produced if it were completed.
The authors assume that the cash flows last forever allowing them to value the completed project
using a continuously compounded version of the growing perpetuity formula. On the other hand,
Schwartz (2004) implements a simulation approach to value patents and patent-protected R&D
projects assuming two stochastic differential processes, one of them for the cost-of-completion and the
other for the cash flows generated from the project, and introduces the probability of any catastrophic
event with a Poisson probability. In this paper we consider the net cash flow as the underlying
variable, however since this variable takes into consideration the production and marketing cost it
could yield a negative cash flow stream. Therefore, we assume that the net cash flow of a successful
project is given by an Arithmetic Brownian motion process plus a time dependent component depicts
by the Fourier series. On this regard, Copeland and Antikarov (2001, Chapter 5) claim that cash
flow streams, and thus present values, can be negative. Accordingly, Alexander et al. (2012) assume
that the project’s value does not necessarily remain positive during the whole project’s life and
model the intrinsic value of the project with an Arithmetic Brownian motion process which allows
the underlying to become negative. Under this assumption, the authors find analytical formulas for
European calls and puts on dividend-paying assets and provide a numerical algorithm for American-
style options based on an Arithmetic Brownian motion process. It is worth point out that in this
paper we model the stochastic process with an Arithmetic Brownian motion because we intentionally
decided to model the net cash flow as the underlying variable, however the methodology applied here
can be easily extrapolate to any other underlying variable following a Geometric Brownian motion
or a mean reverting process.
An important feature of R&D projects is the uncertainty related with the cost to completion,
for an in-depth look of this topic see, for instance, Hansen (1979), DiMasi et al. (1991), and
particularly DiMasi et al. (2003) where the authors perform a thoroughly study of the research
and development cost of 68 randomly selected new drugs of 10 different pharmaceutical companies
and provide an estimate of the costs of pharmaceutical innovation. Also, Pindyck (1993) studies
investment decisions when the project is subjected to two different sources of uncertainty, technical
uncertainty and cost uncertainty. In this case, the author concludes that, although the sources and
3
amounts of cost uncertainty greatly varies across projects, cost uncertainty has a deeper impact than
technical uncertainty in terms of its effect on the investment rule and the value of the investment
opportunity.
Further relevant literature about real option valuation includes, Childs and Triantis (1999) who
examine dynamic R&D investment policies and the valuation of R&D programs in a contingent
claims framework. The authors study the interaction between multiple R&D projects cash flows
and analyse how the firm may alter its funding policy over time. Smith and Nau (1995) compare
the risk-adjusted discount-rate analysis, option pricing analysis, and decision analysis approaches
for valuing risky projects. Posner and Zuckerman (1990) determine the optimal stopping time of an
R&D project and characterize the expenditure strategy assuming a random R&D decision model
without rivalry. McDonald and Siegel (1986) compare the optimal timing of investment for certain
alternative combinations when the future net cash flow follows a Geometric Brownian motion pro-
cess with and without jumps, and the cost of installation is fixed or stochastically modelled with
also a GBM process. Gamba and Trigeorgis (2007) implement a multi-dimensional binomial algo-
rithm for valuing options whose payoff depends on N-dimensional state variables following correlated
Geometric Brownian processes.
3 Pharmaceutical industry and economic risk factors
Economic forces not only affect the number of investment opportunities available in the Pharmaceu-
tical industry but also play a key role in the cash-flow determination of a successful R&D project.
Consequently, economic uncertainty represents an essential risk factor affecting Pharmaceutical stock
returns. This section is devoted to identify those economic risk factors driving the stock return pro-
cess and the risk premium associated with each individual factor.
There is a vast number of economic risk factors with a potential impact in a Pharmaceutical
company. For the sake of simplicity, in this paper we analyse two major forces. Firstly, as discussed
in Fama and French (1989) the term yield spread (TYS) tracks the business cycle, therefore it
constitutes a relevant force to be considered in the analysis. The TYS is computed as the yield
difference between 10-year and 3-month Treasury constant maturity provided by the Federal Reserve
database. As for the second force proxy we employ the VIX index, provided by the Chicago Board
Options Exchange CBOE, which is considered as the barometer of investor sentiment and market
volatility. As will be the case, each of these time series might arise as the interaction of factors with
different characteristics, in particular, the interaction of factors with different periods. In order to
disentangle this interaction, we perform an spectral analysis of each time series and we search for
those factors with higher spectral density.
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Figures 1 and 2 present the demeaned TYS and VIX series, respectively, and the corresponding
spectra.a As for the TYS series, the spectrum reveals four dominant frequencies driving the process,
those frequencies are 0.0302, 0.1209, 0.1813, and 0.4231, indicating a period of 33, 8, 5.5, and 2.4
years, respectively. The business cycle is normally associated to a period of 8 years, not surprisingly
the highest power spectral density corresponds to this frequency. Moreover, there is a second spectral
peak at the frequency corresponding to the 5.5 years period. This period may be associated to the
Kitchin cycle which accounts for time lags in information movements, for further information about
the Kitchin cycle we refer to the original paper Kitchin (1923). As for the other two frequencies, the
power spectral density still stands out from the noise but the relevance decreases, in any case the
underlying frequencies reveal a long run and a short period of 33 and 2.4 years, respectively.
On the other hand, the spectrum associated with the VIX series presents a not well defined peak
at a rather short frequency. In fact, the full width at half maximum (FWHM) goes from 0.06 to
0.185 frequency, that is a period ranging from 5.4 to 16.5 years.
[FIGURES 1 and 2 AROUND HERE]
In order to replicate the TYS and VIX series we consider a Fourier series with four and one term
in the expansion, respectively, that is
FSTY S(t) = A1 · cos (2πf1 · t+ φ1) +A2 · cos (2πf2 · t+ φ2) +A3 · cos (2πf3 · t+ φ3)
+A4 · cos (2πf4 · t+ φ4) (1)
f1 = 0.0302; f2 = 0.1209; f3 = 0.1813; f4 = 0.4231
FSV IX(t) = B1 · cos (2πg1 · t+ ϕ1) (2)





















VIXt − FSV IX(t)
)2
(4)
Since the VIX’s spectra does not provide a well define peak, we estimate the frequency imposing
a boundary condition to the FWHM space, that is g1 ∈ [0.06, 0.185]. Tables 1 and 2 provide the
parameters estimates.
aWe analyse the demeaned series in order to avoid a spectral peak at the zero frequency
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[TABLES 1 and 2 AROUND HERE]
Figures 3 and 4 show the time evolution of the demeaned TYS against the Fourier series with
two and four terms in the expansion, respectively. Figure 5, on the other hand, presents the time
evolution of the demeaned VIX against the Fourier series with only one term in the expansion.
[FIGURES 3 to 5 AROUND HERE]
Hence, we identify each term in the Fourier expansion as a possible factor in the determination
of the excess of return. In order to test the relevance and the premium associated with an individual
factor we will use the Fama-MacBeth test proposed by Fama and MacBeth (1973). The two stage
Fama-Macbeth regression estimates the premium rewarded to a particular risk factor exposure, that
is, how much return you would expect to receive for a particular beta exposure to that factor. The
first stage regressions are a set of time series regression of each asset or portfolio’s return on the
factors, that is
rei,t = αi +
∑
j
βi,j · Fjt + ǫit (5)
where rei represents a t×1 vector of excess of returns, Fjt is a t×j matrix of factors, βj,i represents
a j × 1 vector of factor loadings, αi is the intercept, j and i represent the number of factors and the
number of assets or portfolios, respectively. This regression reveals to what extent each asset’s or
portfolio’s return is affected by each factor.
The second stage regressions calculate the premium rewarded to each factor exposure following
a set of cross-sectional regressions
reit = λ0t +
∑
j
λjt · βij + ηit (6)
where the independent variables, βij , are always the same for every regression, each λtj is a t× 1
vector of factor premium, and λ0t is the intercept. Note that for each factor we have a time series






where λ¯j and σ¯j represent the mean and standard deviation of each factor premium and T is the
length of the time series.
First, we analyse the premium associated to each individual factor by itself. Table 3 presents
the estimated premium and significance of each factor individually. Results reveal that, in this
analysis, the risk factor of 33 years period is the only factor where the null hypothesis cannot be
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rejected (H0 : λ = 0). Furthermore, in Table 4 we analyse the four factors associated with the
TYS and the factor associated with the VIX series all together, and also different combinations of
factors. We can see that, systematically, the null hypothesis cannot be rejected for the 33 years
period factor, which indeed cannot be consider as a relevant factor. In contrast, factors with period
5.5 and 2.4 years consistently deliver significant premiums for most factor combinations. On the
other hand, an interesting analysis arises regarding those factors with 8 and 10 years period. We
can see that both factors provide significant premiums when they are analysed individually, however
when we incorporate further factors in the analysis the significance level decreases. Indeed, this may
be indicating some sort of cointegration between factors. To sum up, in terms of asset valuation,
we can see that the three factors basket composed of λ2, λ3, and λ4, that is the factors with the
underlying period of 2.4, 5.5, and 8 years, provides a combination where all three premiums rewarded
are statistically significant at least at 10%.
[TABLES 3 and 4 AROUND HERE]
4 R&D valuation model
Consider, for instance, a pharmaceutical R&D project for the development of a new drug. The very
nature of such project and the potential impact on human health make the pharmaceutical industry
quite unique and risky. There are several strict and well regulated stages since the early-stage drug
discovery up to the marketing approval and market launch of the product. Figure 6 presents an
illustrative schedule of a generic pharmaceutical R&D project.
[FIGURE 6 AROUND HERE]
The overall project’s life can be divided into two mayor phases, firstly the research and develop-
ment phase and secondly the market phase. During the early-stage of the research and development
phase, a new compound which may potentially derive into a marketable drug is either discovered
or designed. Once the compound is successfully identified as a potential drug and synthesized the
project moves to the next stage. During the preclinical and clinical development the drug must
successfully complete a number of well regulated stages. Firstly, the preclinical stage covers the
laboratory and animal testing, and it is normally during this stage when the company applies for a
patent. If and only if the drug successfully completes the preclinical stage, it accesses the clinical
stage which can be divided into clinical phase I, II, and III. During the clinical phase I, the drug
or treatment is tested in a small group of healthy volunteers in order to determine the safe dosage,
evaluate its safety, and to identify possible side effects and toxicity. During the clinical phase II, the
drug or treatment is tested on a relative large group of subjects (100-300) with the condition that
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the drug is intended to treat in order to further evaluate its safety and efficacy. Finally, the clinical
testing phase III consists of large scale trials, usually a few thousands, to confirm the safety and
efficacy of the drug or treatment and to further monitor possible side effects. The final stage in the
research and development phase is the marketing approval, once again if and only if the drug has
successfully completed each and every preceding stage, the regulatory authority decides whether the
drug is approved for patient use or not. If the marketing approval is granted the project moves to
the market phase where the appropriate marketing strategy should be established and the product
is market launched.
During the patent’s life, the company is entitled to a set of exclusive rights protecting the project
from market competitors for a limited period of time. However, market competition is not the only
force that jeopardises the successful completion of the project. It is well established in the literature,
see for instance Brealey and Myers (2000), that an R&D project faces two different sources of risk,
those are the economic and technical risk. Technical or technological risk takes into account the
inherent uncertainty about the successful completion of each stage during the drug development
phase, for instance, an extreme side effect during the clinical testing would lead to a failure event.
On the other hand, economic risk deals with both market uncertainty such as sales volume, pricing
levels, market competitors, and other economic factors such as interest rates, inflation, growth rate.
Indeed, in order to effectively value these sort of projects we have to be able to properly capture
both sources of risk at the appropriate time.
4.1 Technical uncertainty
Technical or technological risk is the primary source of uncertainty during the drug development
process, in fact, most drugs undergoing the preclinical and clinical stage do not obtain the regulatory
authority’s approval. Since each stage must be preceded by the successful completion of the previous
one, the failure of one stage produces the overall project termination. On the other hand, we
assume that once the drug successfully passes the preclinical and clinical test and finally achieves the
regulatory authority’s approval technical risk virtually vanishes. On this regard, it is widely spread
the use of a Poisson process to model technical or technological risk (see for instance Pennings and






where λ > 0 is the Poisson parameter, and k = 0, 1, 2, ...,∞ defines the number of events.
Generalizing k = 1, 2, ...,∞ as any possible technical event and k = 0 as no technical event, we have
that
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Probability of success = e−λ (9)





= 1− e−λ (10)
Hence, the expected project value conditional to technical risk is given as






• Vt(k = 0) is the value of a successful project
• Vt(k = 1, 2, ...,∞) is the residual value of a failing project
Note that a failed project might increase the stock of knowledge of the company. However, it is
common use to assume that the outcome of a failure is a worthless project. Under this assumption,
technical risk can be consider as a premium over the risk free rate and during the development
process the discount factor is given by e−rdt = e−(r+λ)t, where λ represents the annual rate of failure
and r the risk-free rate. Note that, as stated above, technical risk vanishes after the regulatory
authority’s approval, hence this premium is only valid during the drug development phase.
4.2 Economic and market uncertainty
So far things are fairly easy but we have only dealt with technical risk. Economic risk takes into
account those factors affecting market conditions, not determining the successful completion in
technological terms but defining the cash flow structure of a successful project which gives rise
to the project’s abandon option. In this fashion, economic risk not only comprehends macro and
microeconomic figures but also certain project specific forces and circumstances driving the cash
in and out flow, for instance an outbreak of influenza would drive an increase in market sales for
those specific medicines or the 2014 Ebola outbreak that pushed the use of the experimental drug
“ZMapp” in humans. Note that we have intentionally used the sentence “successful project”, that
is because we have divided the project into two mayor phases, the research and development and
the market phase. As stated above, during the research and development phase technical risk is the
dominant source of uncertainty and it vanishes as the drug successfully overcomes every single stage
in the development process and finally achieves the corresponding approval, those projects reaching
the market phase are the “successful projects”. Once the drug reaches the market phase, there are
several forces playing a significant role and we have called this source of uncertainty economic risk,
however it is important to remember that only a “successful project” will face economic risk.
9
We can easily realise that measuring economic risk is not a trivial endeavour, in fact, creating
a framework where every force affecting the project is considered is literally impossible. On this
regard, it is common use to model the evolution of the project or the evolution of the cash flow as
a stochastic differential equation
dCt = µ(C, t)dt + σ(C, t)dW (12)
where the process can take the form of a Geometric Brownian motion, Arithmetic Brownian
motion, or an Ornstein-Uhlenbeck process. We can also find a more realistic and sophisticated
framework, as the one proposed by Schwartz (2004), where the author models both the cash flow
and the cost of completion with a stochastic differential equation.
As long as we stick with one stochastic factor, all these models share that the only source of
uncertainty comes from a random walk weighted by σ(C, t), that is the diffusion term.b It seems
fairly obvious that a simple diffusion model cannot account for a realistic variety of forces playing
a key role during the project’s market phase. In particular, neither of these models can properly
account for any seasonal component which, for instance, plays a primary role in the outbreaks of the
flu, plus neither consider the effect of the business cycle nor any other relevant force. At this point
it is worth to wonder whether such models are an oversimplification and which forces do really make
an impact in terms of project valuation. Of course there is not one right answer, each project must
be analysed in excruciating detail to determine the appropriate set of relevant forces, but it seems
fair to conclude that a simple diffusion model is just a naive simplification of the market structure.
In what follows we consider that the net cash flow stream, Ct, of a successful project is given
by a latent variable, Yt, depicted by an Arithmetic Brownian motion process plus a time dependent
component described by the Fourier series, that is
Ct = f(t) + Yt (13)
dYt = µdt+ σdWt (14)
f(t) = Fourier Series (15)










bThe option pricing literature is very fructiferous in terms of models with two, or even three stochastic factors, see
for instance Chen 1996
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The net cash flow stream takes into consideration the production and marketing cost, in con-
sequence it could yield a negative rate, thus an Arithmetic Brownian motion process is a suitable
representation of the underlying process. Under this framework, the solution of the underlying pro-















where WQt is a standard Wiener process under the risk-neutral measure P
Q.
In the same fashion as in Schwartz (2004), the cash flow stream starts when the R&D project
is market launched, before this stage the process describes the net cash flow that the project would
have produced if it were successfully completed. Once the medicine or treatment is market launched
the value of the project depends exclusively on the net cash flow generated. Hence, using the












− rV = 0 (19)
subject to the appropriate terminal condition V (C, T ), where T represents the patent expiration.
The novel component in this model is the ad hoc incorporation of the Fourier series, f(t), ac-
counting for any economic, market, and specific force affecting the project and not captured by the
underlying stochastic differential equation. In this sense Fourier series should be considered as an
aggregate of forces playing a relevant role in the process evolution and determining the cash flow
structure. Note that Fourier series provides a great deal of flexibility as, by Carleson’s theorem, it
converges almost everywhere for a L2 function. Therefore, f(t) allows us to properly define a sce-
nario where the project will be developed, such scenario is tailor made based on the characteristics
of each project, the influence and exposure to certain forces, and so on. On this regard, we might
not have a precise ex-ante projection of such scenario, for instance, we might know that the business
cycle represents a risk factor but we might not know how deeply it affects the cash flow stream.
Hence, let us represent the economic uncertainty by the state vector
Φ(j) with j ∈ N (20)
where each state defines a case scenario depicted by a concrete selection of terms in the Fourier
expansion and represents the aggregate of forces. It is important to stress out that a state scenario
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does not attempt to replicate a precise future outcome but rather establishes an alternative future
development. Each state determines the cash flow structure of a successful project and consequently
the managerial decision of ceasing or continuing the project. Thus, the expected patent value
conditional to a certain economic state is given as
V
(







with j ∈ N (21)
where Ct and It represent the net cash flow structure once the drug obtains the marketing
approval and the investment structure during the research and development phase, respectively.
Note that the conditional patent value is constrained to the future development of certain state,
which of course is uncertain. Therefore, since Φ is defined as a discrete state vector, an essential
piece of the puzzle is the appropriate definition of its mass probability function. On this regard,
Huchzermeier and Loch (2001) define a one-dimensional parameter i to model the product perfor-
mance. The authors claim that this performance may unexpectedly improve with probability p, or
it may deteriorate with probability (1 − p) and they generalize the binomial distribution by allow-
ing the performance “improvement” and “deterioration” over N performance states. We can easily
accommodate a similar probability mass function defining two states in the economic state vector,
that is, j = 1, 2. However, as stated above, each state represents the aggregate of forces acting over
the project, and therefore is very project specific, so we will implement a rather Bayesian approach
and assign a prior probability to each scenario. Note that each state can be defined in several ways,
we can tailor made it based on our own expectations, we can define it based on analyst expectations,










where pj represents the probability that the state Φ
(j) turns out real. Hence, under this frame-














4.3 Risk premia and risk factors
We have already stated that during the research and development phase the dominant source of
uncertainty comes from technical or technological risk. Following a similar approach as Pennings
and Sereno (2011) and Schwartz (2004), we have used a Poisson process to account this source of
risk. We have also pointed out that technical risk can be considered as a premium over the risk-free
rate, for that reason during this stage the discount factor yields e−rdt = e−(r+λ)t. However, we have
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assumed that during the market phase the drug has already achieved the marketing approval and
there is no technical uncertainty. Then, technical uncertainty vanishes, economic and market risk
















Under our model representation the cash flow streams start once the drug is launched and the
net cash flow process of a successful project is given by a latent Arithmetic Brownian motion process
plus a time dependent component depicts by the Fourier series, just as given by equations [13] to
[15].
Let us assume that the excess of return of a pharmaceutical company, that is the premium over
the risk free rate, is a function of the return on every active project. Hence, we can define it as a






where f(t) is given by equation [15], i represents each active project, and j represents each state
in the economic state vector. Note that equation [25] cannot be considered just an aggregate of
equation [24] for several reasons, for instance, there may be a non-linear interaction or synergy across
projects, there may be a project financed with a government grant, or simply those economic and
market forces may affect with different intensity different projects, in this sense it seems reasonable to
assume that the business cycle has a deeper impact over aesthetic medicines than cancer treatments.
Further information about project interactions can be found in Loch and Kavadias (2002) where
the authors develop a dynamic model of resource allocation taking into account multiple project
iterations.
5 Numerical results
This section is devoted to illustrate the numerical implementation of the posited model and method-
ology. Let’s assume that the research team has already identified a compound which may potentially
be used to engineer a new diabetes medication. At this stage the Board has to face the first abandon
option, that is, they have to decide whether this project constitutes a valid investment opportunity
and apply for a patent protection or drop it before going any farther into the development phase.
For the sake of simplicity, let us assume that there is no uncertainty about the time and cost to
completion if the project successfully overcomes every stage in the development process. Note that
most of the investment cost is spent to develop the drug and it can also be modelled stochastically,
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see for instance Schwartz (2004). However, we prefer to keep the numerical example as simple as
possible and focus the attention on economic and market uncertainty rather than development is-
sues, although a stochastic process for the cost and time to completion could be easily implemented.
According to the “Tufts Center for the Study of Drug Development” (see DiMasi et al. 2014), the
total out-of-pocket cost per approved new compound is about 1.400 Millions (in 2013 $). Based on
this information, Table 5 summarises the representative out-of-pocket investment cost and schedule
by year.
[TABLE 5 AROUND HERE]
5.1 Technical uncertainty
In the previous section we have established that during the development phase the project can
either fail or be abandoned. Technical risk accounts for the probability of a failure event due to
a technical or technological reason within the development phase, and we have generalized the
Poisson distribution allowing for the probability of success and technical failure. According to the
“2015 biopharmaceutical research industry profile” report, provided by PhRMA, the average time
to develop a drug is about 10 years and the percentage of drugs entering clinical trials resulting in an
approved medicine is less than 12 %. Hence, assuming that only 12 % of such projects successfully
overcome every stage in the development phase and a development period of 10 years, the annual
rate of failure is given as
e−10·λ = 0.12 (26)
λ = 0.2120 (27)
We have also assumed that the outcome of a failure is a worthless project, hence, during the
development process the discount factor is given by e−rdt = e−(r+0.2120)t, where r represents the
risk-free rate.
5.2 Economic and market uncertainty
We have determined that the net cash flow stream from sales revenues, marketing and production
cost starts when the medication gets the marketing approval and it is launched, which is expected to
occur on period 10. Let us assume that the patent will be granted in 4 years for a limited period of
20 years. When the patent expires market competition forces sales to virtually zero, meaning that
based on the schedule the company can only benefit from this project for 14 years starting at market
launch. This assumption generates the boundary condition, V (T ) = 0, on equation [19], where T
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represents the patent expiration. Furthermore, in section 3 we have performed a Fama-MacBeth
test and we have identified the economic risk factors driving the valuation process, those are the
factors with period of 2.4, 5.5, and 8 years, and we have estimated the parameters in the Fourier
expansion as given in Table 1. Note that the parameters defining the behaviour of the economic
force, and hence of each factor, are the frequency (f) and the phase (φ) parameter. On the other
hand, the amplitude parameter defines the intensity of such force or cycle over the net cash flow
stream, indeed a project dependent parameter.
Let us define three states in the economic state vector, each of them will represent an economic
benchmark determined by the top-3 best selling diabetes medicines commercialized by American
Pharmaceuticals, these are
• Φ1 : g (Φ1) = 1/3⇒ Scenario 1: Januvia (Merck & Co., Inc.)
• Φ2 : g (Φ3) = 1/3⇒ Scenario 2: Janumet (Merck & Co., Inc.)
• Φ3 : g (Φ2) = 1/3⇒ Scenario 3: Humalog (Eli Lilly and Company)
Figure 7 presents the quarterly sales revenue from 3Q-2009 to 1Q-2015 of each medicine. For
each state, we consider that the initial cash flow parameter, C0, in equation [18] is given by the sales
revenue at time 3Q-2009, and we proxy the volatility, σ, by the standard deviation of the process,
hence
Φ1 ⇒ C0 = 490 Million$ and σ = 200 Million$ (28)
Φ2 ⇒ C0 = 173 Million$ and σ = 115 Million$ (29)
Φ1 ⇒ C0 = 500 Million$ and σ = 75 Million$ (30)
[FIGURE 7 AROUND HERE]
Moreover, considering the three economic risk factors defined in Section 3, we defined the Fourier
component in equation [15] under each state scenario as follows
f(t | Φ1) = Aˆ10 + Aˆ12 · cos (2πf2 · t+ φ2) + Aˆ13 · cos (2πf3 · t+ φ3) + Aˆ14 · cos (2πf4 · t+ φ4) (31)
f(t | Φ2) = Aˆ20 + Aˆ22 · cos (2πf2 · t+ φ2) + Aˆ23 · cos (2πf3 · t+ φ3) + Aˆ24 · cos (2πf4 · t+ φ4) (32)
f(t | Φ3) = Aˆ30 + Aˆ32 · cos (2πf2 · t+ φ2) + Aˆ33 · cos (2πf3 · t+ φ3) + Aˆ34 · cos (2πf4 · t+ φ4) (33)
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, and the frequency and phase parameters as given in Section 3-Table 1. Table
6 provides the estimates of the intensity parameters under each state scenario.
The three state scenarios share the same risk-free rate. The usual benchmark for the risk-free
rate is the treasury constant maturity provided by the Federal Reserve, however since the beginning
of the financial crisis the US treasury yield is close to zero. Hence, we will use a risk-free rate of
1.5% although the current value is much lower.
5.3 Project value and risk management
Having defined the state vector and calibrated all the input parameters, we are ready to compute
the value of this project. As shown in Figure 7, the market data of each benchmark medicine is
provided in quarters. Hence, by assumption, we consider that the underlying process, Ct, defines
the quarterized net cash flow stream. Then, we simulate each path considering a time increment of
∆t = 1/4, that is quarterly increment. The discrete cash flow at any time t is given by equation
[18]. Once the marketing approval is granted, the marketing and production cost are accounted into
the net cash flow process. Therefore, discounting all the discrete cash flows up to market launch
and summing them up could yield an aggregated negative value, for that reason it is considered an
abandon option at market launch although there is no further investment in developing the drug.
Note that the probability of an aggregated negative cash flow at market launch is the consequence
of considering an Arithmetic Brownian Motion process plus the impact of the Fourier component
over such process, therefore such probability tends to decrease as the economic state improves.
Accordingly, at market launch the abandon option is given by
V
(







Ct · e−r(t−tML) , 0
}
(37)
where tML and T represent the market launch and patent expiration time, respectively.
The exercise time for the subsequent abandon options is defined on yearly basis and the option
is evaluated conditional on not having been abandoned before, therefore the time increment during
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the development phase is give by ∆t∗ = 1. The backward procedure consists on discountingc the
project value to the exercise time and evaluating the optimal abandon option, that is
V
(







t+∆t∗, Ct+∆t∗ , It+∆t∗ ; Φ
(j)
)
· e−(r+λ)∆t∗ − It , 0
}
(38)
The procedure continues rolling back up to the present time for those paths that are not optimally
abandoned on previous interactions.
Considering 100.000 path simulations and following the above mentioned procedure, the expected
patent value conditional to each state in the economic state vector is given as in Table 7
[TABLE 7 AROUND HERE]
Note that, considering the state mass probability function and equation [23], the unconditional
Patent value is given by
Patent Value with abandon option = 4374 × 1/3 + 2045 × 1/3 + 2901 × 1/3
= 3106 Millions $ (39)
Patent Value without abandon option = 3864 × 1/3 + 1564 × 1/3 + 2854 × 1/3
= 2761 Millions $ (40)
Just as expected, we can clearly see that the abandon option has a significant effect over the
overall project value. Moreover, comparing panel A with B, and C with D in Table 7, we can disag-
gregate the abandon option effect by state. Although, the abandon option has a deep impact over
states 1 and 2, the effect over state 3 is rather small. Since the three states share the same investment
cost schedule, the small influence of the abandon option over state 3 arises as a combination of two
parameter, in this particular case a high initial cash-flow (C0 = 500 Million $) and a rather small
volatility (σ = 75 Million $). The effect of the initial cash-flow over the abandon option is fairly
obvious, but the incidence of the volatility is somehow subtle. Increasing the volatility parameter
derives in a much uncertain state, meaning that the cash flow stream could yield a much larger or
smaller than expected value. The upside risk, that is the risk of obtaining a higher than expected
cash flow, increases the project value. On the other hand, the downside risk, that is the risk of
obtaining a smaller than expected cash flow or even a negative cash flow, is limited by the abandon
cNote that during the development phase the discount factor is given by e−rdt = e−(r+λ)t, where λ represents the
annual rate of failure and can be considered as a technical or technological risk premium.
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option. Hence, in terms of real options valuation, increasing the volatility derives in a higher project
value because we are increasing the upside risk while the downside risk is limited, this effect is mea-
sured by the greek “Vega” which will be analysed in further detail later on. Furthermore, comparing
panel A with C, and B with D in Table 7 we can analyse the effect of the economic force over
each state. As stated in the previous section, the impact of the economic force might varies across
projects and states. Indeed, we can see that the economic force boosts the value of states 1 and 2,
notoriously it has a negative effect over state 3. This effect might be explained by the sensitivity of
each Pharmaceutical company to economic and market conditions, we have to remember that states
1 and 2 correspond to the benchmark medicines Januvia and Janumet, respectively, both of them
commercialized by Merck & Co., Inc. On the other hand, state 3 corresponds to Humalog which is
commercialized by Eli Lilly and Company.
Moreover, Table 8 disaggregates by state and period the number of paths optimally abandoned,
that is the number of abandon options exercised. We have already stated that the first exercise
date is at market launch. Since the net cash flow stream takes into consideration not only the sales
revenues but also the production and marketing cost this variable can, and indeed does, become
negative for some paths. Hence, it may be optimally exercised the abandon option although there is
no further investment in developing the drug at market launch. In fact, out of 100.000 simulations
this is the case for 17.997, 22.277, and 2.837 paths in the Φ1, Φ2, and Φ3 state, respectively. Of
course, the likelihood of exercising the abandon option at market launch increases as the economic
state worsens and vice versa. Conditional on not having been abandoned before, the abandonment
decisions at each period are fully determined by the investment schedule and the economic state.
Furthermore, the aggregated abandon rate by state is 20.65%, 27.56%, and 5.01% for the Φ1, Φ2,
and Φ3 state, respectively.
[TABLE 8 AROUND HERE]
Tables 9 to 11 present the conditional state value variation with respect to changes in C0 and σ,
while Figures 8 to 10 show the consequent sensitivity surface. From the option pricing literature we
know that the greek “Vega” tells in what direction and to what extent the option price will move
if there is a positive change in the volatility parameter, and only in this parameter. Furthermore,
we also know that Vega is always positive regardless if it is a put or call option. Looking the tables
by columns, that is the patent value for different choices of the volatility parameter and fixed initial
cash flow, we can clearly see that in every case the patent value increases as the volatility does.
A more obvious result is revealed looking the tables by rows, that is the patent value for different
choices of the initial cash flow parameter and fixed volatility, we see that the patent value increases
as the initial net cash flow does.
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[TABLES 9 TO 11 AROUND HERE]
[FIGURES 8 TO 10 AROUND HERE]
Besides, Figure 11 presents a stress test analysis, that is how the patent value reacts to changes







= 1. This figure is quite revealing, indeed it covers the whole economic
subspace and tells us how the patent value varies to any possible combination of intensities in the
economic force. However, for any economic state vector with more than three components, that is
j ≥ 4, the figure will produce a hyper-volume in a j−dimensional space.
[FIGURE 11 AROUND HERE]
Finally, Figure 12 presents the cash flow histogram by state at two different points in the market
phase, these are Market launch and Patent expiration. The dispersion in the distribution is a direct
consequence of the estimated volatility, thus state 1 presents a much more dispersed distribution
than state 3, both at Market launch and Patent expiration, deriving in a higher value of the abandon
option. Furthermore, the red dotted line represents the mean cash flow distribution, which is fully
determined by the economic impact and the initial cash flow.
[FIGURE 12 AROUND HERE]
6 Concluding remarks
In this paper we have developed a novel valuation model and methodology to value a pharmaceutical
R&D project based on real options approach. The posited model takes into account the interaction
of market and economic forces, and the effect of these risk factors in terms of asset pricing. In
Section 3, we have identified those economic risk factors driving the stock return process and the
risk premium associated with each individual factor. For this endeavour we have analysed two major
economic forces, namely the term yield spread and the VIX index, and we have disentangled the
interaction of risk factors via spectral analysis. Our findings show that exposure to those factors
with period 2.4, 5.5, and 8 years provide significant premium rewarded and should be consider in
the valuation process.
In order to incorporate these risk factors and account for economic risk, we have incorporated
a novel economic state vector where each economic state captures the interaction among different
market and economic forces using Fourier series as the particular basis for the economic function
space. In this sense, Fourier series allows us to properly define an economic scenario where the
project will be developed and it is considered as an aggregate of forces playing a relevant role in
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the process evolution and determining the cash flow structure. On this regards, Fourier series is a
powerful mathematical instrument which allows us to define the economic state scenario as much
sophisticated as we want increasing the number of forces affecting the evolution of the project. In
fact, Fourier series provides a great deal of flexibility as, by Carleson’s theorem, it converges almost
everywhere for a L2 function.
In Section 5, we have illustrated the application of this model and methodology with a simple
numerical example which attempts to value an R&D project to engineer a new diabetes medication.
To keep the example as simple as possible we have only considered three different states in the
economic state vector, each of them represents an economic benchmark determined by the top-3
best selling diabetes medicines commercialized by American Pharmaceuticals, these are Januvia,
Janumet, and Humalog, the first two commercialized by Merck & Co., Inc., and the third one by Eli
Lilly and Company. Under this framework, we have performed 100.000 path simulations for each
economic state and we have valued the aforementioned project. Furthermore, we have performed a
sensitivity and stress test analysis for some relevant parameters and we have compared the valuation
results with the project value obtained with and without the economic risk factors and with and
without the abandon option.
The model and methodology presented in this paper constitute a powerful and yet simple valu-
ation instrument with strong practical applications. As stated above, the pharmaceutical industry
is extremely complex and competitive and most companies have to choose with financial wisdom
each project. There are several forces, both economic and technical, driving the drug development
process that are not fully understood. On this regards, our proposed model tackles all those forces
playing a significant role in the project valuation process in a very simple manner and provides a
comprehensive tool for the decision making process. The model and methodology here proposed can
be easily extrapolated to any other industry or corporate project.
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f1 = 0.0302 Period ≈ 33 years
A2 = 0.9256(0.0074)
φ2 = 3.4761(0.0079)
f2 = 0.1209 Period ≈ 8 years
A3 = 0.6949(0.0076)
φ3 = 0.4706(0.0154)
f3 = 0.1813 Period ≈ 5.5 years
A4 = 0.3704(0.0074)
φ4 = 3.8037(0.0198)
f4 = 0.4231 Period ≈ 2.4 years
Table 1: This table presents the four terms Fourier expansion parameters estimates for the Term Yield
Spread time series.




g1 = 0.0970(0.0003) Period ≈ 10 years
Table 2: This table presents the one term Fourier expansion parameters estimates for the VIX time series.
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Factors premium
Period (years) - 33 8 5.5 2.4 10
1 Factor λˆ0 λˆ1 λˆ2 λˆ3 λˆ4 λˆ5
Mean 0.9654 0.1194 - - - -
t-stat 1.5817 0.6528 - - - -
Mean 1.1648 - 1.3547 - - -
t-stat 2.7970 - 2.4566 - - -
Mean 1.0749 - - 0.7097 - -
t-stat 2.6499 - - 2.6681 - -
Mean 1.3411 - - - -0.8503 -
t-stat 3.0361 - - - -2.2970 -
Mean 2.6163 - - - - 1.7877
t-stat 3.3248 - - - - 2.6027
Table 3: This table presents the estimated premium rewarded to a particular risk factor exposure.
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Factors premium
Period (years) - 33 8 5.5 2.4 10
5 Factors λˆ0 λˆ1 λˆ2 λˆ3 λˆ4 λˆ5
Mean 1.9564 -0.3236 -1.4373 1.4821 -0.8993 -0.7369
t-stat 2.3342 -1.2012 -1.0422 2.1351 -2.3204 -0.7079
4 Factor λˆ0 λˆ1 λˆ2 λˆ3 λˆ4 λˆ5
Mean 2.1609 - -1.2958 1.5219 -0.8353 -0.6421
t-stat 2.4200 - -1.0125 2.1019 -2.3579 -0.6550
Mean 1.9656 -0.3079 - 1.5327 -0.8895 -0.8114
t-stat 2.3660 -1.1727 - 1.8712 -2.4153 -0.6541
Mean 2.1254 -0.2685 -1.2407 1.4610 -0.8711 -
t-stat 2.4934 -1.0687 -1.0605 2.1741 -2.3909 -
3 Factors λˆ0 λˆ1 λˆ2 λˆ3 λˆ4 λˆ5
Mean 2.5676 - - 0.2685 -0.8984 1.6996
t-stat 2.3745 - - 0.7618 -2.4194 1.5496
Mean 0.9642 - -3.8231 2.4420 -0.6819 -
t-stat 2.4057 - -1.6268 2.1164 -1.9421 -
Mean 2.3439 -0.3112 - 0.9700 -0.9092 -
t-stat 2.5206 -1.1811 - 2.8070 -2.4006 -




Development Preclinical Clinical Clinical Clinical Regulatory
stage testing Phase I Phase II Phase III review
Period 0 1 2 3 4 5 6 7 8 9
Investment 60 60 82 82 196 196 174 174 174 11
Table 5: This table presents the work schedule and budget for the whole development process including the regulatory approval.
Intensity parameters estimates. Meds
Estimates
Factor 2 Factor 3 Factor 4
Medicine ~1
Period ≈ 8 years Period ≈ 5.5 years Period ≈ 2.4 years
Januvia Aˆ10 = -608.0681 (43.9219) Aˆ
1
2 = 8.1830 (3.1416) Aˆ
1
3= -19.3515 (4.1493) Aˆ
1
4 = -18.0127 (10.1329)
Janumet Aˆ20 = -558.3166 (11.1398) Aˆ
2
2 = -0.9269 (0.7596) Aˆ
2
3= -2.8288 (0.2174) Aˆ
2
4 = 0.3097 (1.2646)
Humalog Aˆ30 = 87.8557 (0.6163) Aˆ
3
2 = -4.8234 (0.9429) Aˆ
3
3 = -8.3032 (0.0000) Aˆ
3
4 = 11.8428 (0.6504)
Table 6: This table presents the intensity parameters estimates to a particular economic risk factor for a particular benchmark medicine.
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Conditional Expected Patent Value
Economic Panel
State A B C D
V
(
t, Ct, It; Φ
(1)
)
4373.5044 (12.2098) 3864.3235 (14.6124) 3615.1780 (11.3771) 2851.5395 (14.7052)
V
(
t, Ct, It; Φ
(2)
)
2044.6319 (6.5133) 1564.4866 (8.4452) 1452.3542 (5.6570) 699.4146 (8.4700)
V
(
t, Ct, It; Φ
(3)
)
2900.8647 (5.2686) 2853.5092 (5.5206) 2953.2034 (5.2786) 2917.4724 (5.5200)
Patent Value (error) 3106.3337 (4.9358) 2760.7731 (5.9191) 2673.5785 (4.5863) 2156.1422 (5.9484)
Table 7: This table presents the patent value conditional to each state in the state vector.
Panel A: With Fourier component and with abandon option
Panel B: With Fourier component and without abandon option
Panel C: Without Fourier component and with abandon option
Panel D: Without Fourier component and without abandon option28
Abandon rate
Development Preclinical Clinical Clinical Clinical Regulatory Market
stage testing Phase I Phase II Phase III review launch
Period 0 1 2 3 4 5 6 7 8 9 10
Investment 60 60 82 82 196 196 174 174 174 11 0
336 295 320 239 489 357 253 201 159 6 17997
Scenario 1
20652 20316 20021 19701 19462 18973 18616 18363 18162 18003 17997
721 560 597 558 894 685 537 396 327 12 22277
Scenario 2
27564 26843 26283 25686 25128 24234 23549 23012 22616 22289 22277
363 249 261 182 369 297 198 145 101 6 2837
Scenario 3
5008 4645 4396 4135 3953 3584 3287 3089 2944 2843 2837
Table 8: This table presents the number of optimally abandoned projects out of 10.000 path simulations. In light gray the disaggregated by





440 450 460 471 480 490 500 510 520 530
σ
150 3796 3860 3900 3981 4038 4089 4137 4205 4250 4329
160 3850 3922 3968 4032 4073 4124 4189 4264 4303 4376
170 3913 3960 4019 4088 4120 4191 4260 4310 4348 4435
180 3980 4031 4093 4138 4192 4261 4294 4352 4435 4478
190 4031 4075 4162 4204 4253 4314 4399 4410 4478 4541
200 4110 4161 4225 4275 4320 4374 4404 4471 4541 4596
210 4183 4238 4282 4372 4402 4436 4497 4549 4600 4650
220 4284 4319 4364 4404 4474 4511 4571 4611 4652 4766
230 4324 4386 4434 4474 4537 4577 4627 4679 4755 4800
240 4412 4450 4508 4560 4613 4644 4707 4756 4799 4861





130 140 150 160 170 180 190 200 210 220
σ
85 1579 1642 1691 1742 1801 1847 1896 1957 2006 2054
95 1666 1719 1773 1813 1876 1925 1969 2024 2077 2130
105 1734 1794 1848 1894 1939 1979 2034 2085 2133 2195
115 1823 1877 1916 1966 2045 2055 2109 2173 2223 2266
125 1915 1970 1999 2053 2094 2151 2192 2231 2289 2331
135 1993 2042 2085 2136 2183 2214 2287 2316 2380 2418
145 2083 2118 2170 2222 2266 2315 2348 2393 2436 2500
155 2180 2203 2257 2289 2343 2366 2431 2481 2527 2578
165 2247 2295 2328 2389 2438 2463 2496 2580 2604 2660
175 2340 2398 2429 2481 2508 2561 2611 2652 2698 2723





450 460 470 480 490 500 510 520 530 540
σ
35 2525 2597 2661 2722 2791 2864 2929 3002 3068 3135
45 2533 2594 2664 2728 2796 2866 2931 2997 3066 3134
55 2544 2602 2662 2736 2804 2878 2934 3000 3069 3141
65 2550 2619 2681 2751 2815 2878 2946 3005 3078 3147
75 2586 2643 2712 2768 2832 2901 2975 3020 3093 3147
85 2613 2677 2742 2814 2867 2931 3001 3062 3112 3184
95 2661 2731 2781 2835 2907 2968 3025 3080 3148 3204
105 2711 2776 2834 2898 2962 3004 3074 3117 3192 3247
115 2770 2821 2875 2936 3000 3049 3112 3185 3239 3287
125 2823 2900 2935 2999 3065 3113 3169 3211 3278 3340
Table 11: This table presents the conditional to state Φ3 patent value sensitivity with respect to σ and C0.
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Appendix of figures










Demeaned Term Yield Spread 
 
 



















Figure 1: This figure presents the demeaned term yield spread time series and its power spectral density.
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Figure 2: This figure presents the demeaned VIX index time series and its power spectral density.
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Demeaned Term Yield Spread Fitting
 
 
Demeaned Term Yield Spread
Two terms Fourier series
Figure 3: This figure presents the demeaned term yield spread time series versus the fitting with two terms in the Fourier expansion.
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Demeaned Term Yield Spread Fitting
 
 
Demeaned Term Yield Spread
Four terms Fourier series
Figure 4: This figure presents the demeaned term yield spread time series versus the fitting with four terms in the Fourier expansion.
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One term Fourier series
Figure 5: This figure presents the demeaned VIX index time series versus the fitting with one terms in the Fourier expansion.
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Figure 6: This figure presents a general pharmaceutical process for the development of a new drug
























































































































































































































Figure 11: This figure presents the unconditional patent value sensitivity with respect to the mass probability
function.
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Cash Flow Histogram at Market Launch
Cash Flow Histogram at Patent Expiration
Figure 12: This figure presents the cash flow histogram by state at both market launch and patent expiration. The red dotted line represents
the mean cash flow distribution.
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